Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects. (Q48452239)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9622623%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

title

Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9622623%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9622623%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

author name string

F P Bymaster

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9622623%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

P A Carter

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9622623%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

S C Peters

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9622623%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

W Zhang

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9622623%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

J S Ward

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9622623%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

C H Mitch

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9622623%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

D O Calligaro

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9622623%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

C A Whitesitt

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9622623%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

N DeLapp

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9622623%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

H E Shannon

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9622623%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

K Rimvall

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9622623%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

L Jeppesen

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9622623%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

M J Sheardown

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9622623%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

P Sauerberg

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9622623%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

language of work or name

English

0 references

publication date

1 June 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9622623%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

number of pages

12

1 reference

based on heuristic

inferred from page(s)

published in

Brain Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9622623%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

volume

795

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9622623%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

issue

1-2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9622623%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

page(s)

179-190

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9622623%20AND%20SRC:MED&resulttype=core&format=json

Phase I clinical trials with WAL 2014, a new muscarinic agonist for the treatment of Alzheimer's disease

12 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

The cholinergic hypothesis of geriatric memory dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

Identification of a family of muscarinic acetylcholine receptor genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

Localization of a family of muscarinic receptor mRNAs in rat brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

Alzheimer's Disease: A Disorder of Cortical Cholinergic Innervation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

Evidence that M3 muscarinic receptors in rat parotid gland couple to two second messenger systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

The muscarinic M1 agonist xanomeline increases soluble amyloid precursor protein release from Chinese hamster ovary-m1 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

WAL 2014--a muscarinic agonist with preferential neuron-stimulating properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

SDZ ENS 163 a novel pilocarpine like drug: pharmacological in vitro and in vivo profile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

SDZ ENS 163 is a selective M1 agonist and induces release of acetylcholine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

Relative affinities of drugs acting at cholinoceptors in displacing agonist and antagonist radioligands: the NMS/Oxo-M ratio as an index of efficacy at cortical muscarinic receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

Direct measurement of muscarinic agents in the central nervous system of mice using ex vivo binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

Muscarinic receptor subtypes: M1 and M2 biochemical and functional characterization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

Cholinergic approaches to the treatment of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

Protein kinase C injection into hippocampal pyramidal cells elicits features of long term potentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

Direct binding studies on ileal and cardiac muscarinic receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

Bioisosteres of arecoline: 1,2,3,6-tetrahydro-5-pyridyl-substituted and 3-piperidyl-substituted derivatives of tetrazoles and 1,2,3-triazoles. Synthesis and muscarinic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

No response to high-dose muscarinic agonist therapy in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

The muscarinic receptor agonist L-658,903 modulates the in vivo accumulation of inositol monophosphates in mouse brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

1,2,5-Thiadiazole derivatives of arecoline stimulate M1 receptors coupled to phosphoinositide turnover

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

Human muscarinic receptors expressed in A9L and CHO cells: activation by full and partial agonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

Activation of m1 muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

Selective inhibition of excitatory amino acid-stimulated phosphoinositide hydrolysis in the rat hippocampus by activation of protein kinase C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

Preclinical and phase 1 clinical characterization of CI-979/RU35926, a novel muscarinic agonist for the treatment of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

Muscarinic M1 receptor agonist actions of muscarinic receptor agonists in rabbit vas deferens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

Safety and tolerability of CI-979 in patients with Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

Z-(±)-1-azabicyclo[2.2.1]heptan-3-one, O-(3-aryl-2-propynyl) oximes as potential m1-subtype selective muscarinic agonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-8993%2898%2900267-4

10.1016/S0006-8993(98)00267-4

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9622623%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference